Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Infanrix) is indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks through 6 years.
• Three studies were analyzed to gather information about the safety and effectiveness of Infanrix.
• A rare case of Guillain-Barre syndrome (GBS) was reported in a child following vaccination with Infanrix; however, the causal relationship between GBS occurrence post-vaccination remains uncertain.
• Maternal Tdap immunization may result in lower IgG levels against pertussis and diphtheria in infants after their own vaccinations compared to those born to unimmunized mothers. Despite this reduction, seroprotection rates remain satisfactory after booster immunizations.
• The use of five-component vaccines like Infanrix has been found more effective than one-component vaccines for adolescents' booster sessions despite having lower antigen doses. This underscores the importance of administering boosters across various age groups beyond childhood for sustained immunity against diseases such as Bordetella Pertussis.
• While there are some considerations regarding adverse events like GBS or the impact of maternal immunization on infant antibody levels that warrant further study, evidence supports the use of Infanrix for comprehensive protection against diphtheria, tetanus, and pertussis across different population groups including adults requiring boosters.